• Connect with us
  • Information
    • About Us
    • Contact Us
    • Careers
    • Partnerships
    • Advertise With Us
    • Authors
    • Browse Topics
    • Events
    • Disclaimer
    • Privacy Policy
  • NORTH AMERICA EDITION
    Australia
    North America
    World
Login
Investing News NetworkYour trusted source for investing success
  • NORTH AMERICA EDITION
    North America
    Australia
    World
  • My INN
Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
  • Reports & Guides
    • Market Outlook Reports
    • Investing Guides
  • Button
Resource
  • Precious Metals
  • Battery Metals
  • Base Metals
  • Energy
  • Critical Minerals
Tech
Life Science
Medical Device Market
Medical Device News
Medical Device Stocks
  • Medical Device Market
  • Medical Device News
  • Medical Device Stocks
medical device investing

MedMira Reports Second Quarter Results

Gabrielle Lakusta
Apr. 03, 2018 09:07AM PST
Medical Device Investing

MedMira (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2018. As quoted in the press release: Revenue: The Company recorded revenues in Q2 FY2018 of $183,876 compared to $193,576 in Q2 FY2017. The slight decrease in revenue was due to the Company’s strategy to focus on high profit margin markets. …

MedMira (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2018.

As quoted in the press release:

  • Revenue: The Company recorded revenues in Q2 FY2018 of $183,876 compared to $193,576 in Q2 FY2017. The slight decrease in revenue was due to the Company’s strategy to focus on high profit margin markets. As outlined below, this strategy has resulted in the Company recording a higher contribution margin and has also indirectly decreased expenses.
  • Gross Profit: The Company recorded a gross profit in Q2 FY2018 of $141,848 compared to $133,652 for the same period last year. The overall gross margin percentage on sales increased by 8% from 69% in Q2 FY2017 to 77% in this financial quarter.
  • Operating expenses: In this quarter, the Company recorded operating expenses of $681,442 compared to $562,527 in Q2 FY2017. The increase of 21% in operating expenses was primarily due to an increase in the Company’s current research and development work on two new products. All other expenses decreased by 20% during this quarter compared to the same period last year.

Click here to read the full press release.

medical device investing financial results
The Conversation (0)

Go Deeper

AI Powered

Trinity Biotech Announces Quarter 3 Financial Results

CanniMed Therapeutics Inc. Reports Financial Results for Q3 2017

Latest News

Outlook Reports

Resource
  • Precious Metals
    • Gold
    • Silver
  • Battery Metals
    • Lithium
    • Cobalt
    • Graphite
    • Electric Vehicles
  • Agriculture
  • Base Metals
    • Copper
    • Nickel
    • Zinc
  • Critical Metals
    • Rare Earths
  • Energy
    • Uranium
    • Oil and Gas
Tech
    • Artificial Intelligence
    • Cybersecurity
    • Robotics
    • Crypto
    • Cleantech
Life Science
    • Biotech
    • Cannabis
    • Pharmaceuticals

Featured Medical Device Investing Stocks

Cardiex Limited

Cardiex Limited (CDX:AU)
CDX:AU

Cleo Diagnostics

Cleo Diagnostics (COV:AU)
COV:AU

Ocumetics Technology

Ocumetics Technology (OTC:CC)
OTC:CC

Avricore Health

Avricore Health (AVCR:CC)
AVCR:CC
More featured stocks

Browse Companies

Resource
  • Precious Metals
  • Battery Metals
  • Energy
  • Base Metals
  • Critical Metals
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES